Utilidad de la ciclosporina en necrólisis epidérmica tóxica: a propósito de un caso.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • Additional Information
    • Alternate Title:
      Cyclosporine-A use in toxic epidermal necrolysis: a case report.
    • Abstract:
      La necrólisis epidérmica tóxica (NET) es una enfermedad mucocutánea, cuya principal etología son el uso de medicamentos. Tiene manifestaciones multisistémicas graves, con mortalidad entre el 25-30%, su identificación y manejo temprano tienen impacto sobre su pronóstico. Dentro de las alternativas para su manejo, está la ciclosporina, un inmunomodulador que demostró una reducción significativa en el riesgo de mortalidad, comparado con el uso de otros inmunomoduladores. Se presenta el caso de una paciente con NET que recibió manejo con ciclosporina, presentando una adecuada evolución clínica. [ABSTRACT FROM AUTHOR]
    • Abstract:
      Toxic epidermal necrolysis (TEN) is a mucocutaneus disease, which main etiology is the use of medication. Due to the severe multisystemic manifestations it has a mortality between 25-30%, reason why early diagnosis and treatment have an impact over its prognosis. As a management option we have cyclosporine, an immunomodulator that has shown a significant mortality reduction compared to the use of other Immunomodulators. Next, we will present the case of a patient with a TEN diagnosis that received cyclosporine and presented significant clinical improvement. [ABSTRACT FROM AUTHOR]
    • Abstract:
      Copyright of Revista de Toxicología is the property of Asociacion Espanola de Toxicologia and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)